These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 16719936

  • 1. Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
    Machold KP, Nell VP, Stamm TA, Smolen JS.
    Arthritis Res Ther; 2006; 8(3):211. PubMed ID: 16719936
    [Abstract] [Full Text] [Related]

  • 2. Assessment and management of rheumatoid arthritis.
    Haraoui B.
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [Abstract] [Full Text] [Related]

  • 3. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 4. Early rheumatoid arthritis -- is there a window of opportunity?
    Cush JJ.
    J Rheumatol Suppl; 2007 Nov; 80():1-7. PubMed ID: 17985417
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H, Kavanaugh A.
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [Abstract] [Full Text] [Related]

  • 9. Innovative treatment strategies for patients with rheumatoid arthritis.
    van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC.
    Curr Opin Rheumatol; 2008 May; 20(3):287-94. PubMed ID: 18388520
    [Abstract] [Full Text] [Related]

  • 10. Unmet needs in rheumatoid arthritis.
    Bykerk V.
    J Rheumatol Suppl; 2009 Jun; 82():42-6. PubMed ID: 19509330
    [Abstract] [Full Text] [Related]

  • 11. Combination treatment strategies in early rheumatoid arthritis.
    Suresh E, Lambert CM.
    Ann Rheum Dis; 2005 Sep; 64(9):1252-6. PubMed ID: 15860511
    [Abstract] [Full Text] [Related]

  • 12. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA.
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [Abstract] [Full Text] [Related]

  • 13. Adherence to biologic DMARD therapies in rheumatoid arthritis.
    Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L.
    Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888
    [Abstract] [Full Text] [Related]

  • 14. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 15. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 16. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y, Shi N, John A.
    Bull NYU Hosp Jt Dis; 2008 Aug; 66(2):77-85. PubMed ID: 18537774
    [Abstract] [Full Text] [Related]

  • 17. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X, Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group, Club Rhumatismes et Inflammation, French Society of Rheumatology.
    Arthritis Rheum; 2009 Apr 15; 61(4):425-34. PubMed ID: 19333993
    [Abstract] [Full Text] [Related]

  • 18. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes.
    Keystone EC.
    Nat Clin Pract Rheumatol; 2006 Nov 15; 2(11):594-601. PubMed ID: 17075598
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun 15; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 20. Early rheumatoid arthritis.
    Mitchell KL, Pisetsky DS.
    Curr Opin Rheumatol; 2007 May 15; 19(3):278-83. PubMed ID: 17414956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.